Emesis (Vomiting) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Emesis (Vomiting) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Emesis (Vomiting) - Pipeline Review, H2 2014', provides an overview of the Emesis (Vomiting)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Emesis (Vomiting)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Emesis (Vomiting) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Emesis (Vomiting) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Emesis (Vomiting)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Emesis (Vomiting) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Emesis (Vomiting) Overview 6
Therapeutics Development 7
Pipeline Products for Emesis (Vomiting) - Overview 7
Pipeline Products for Emesis (Vomiting) - Comparative Analysis 8
Emesis (Vomiting) - Therapeutics under Development by Companies 9
Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes 10
Emesis (Vomiting) - Pipeline Products Glance 11
Early Stage Products 11
Unknown Stage Products 12
Emesis (Vomiting) - Products under Development by Companies 13
Emesis (Vomiting) - Products under Investigation by Universities/Institutes 14
Emesis (Vomiting) - Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
Daewoong Pharmaceutical Co., Ltd. 16
Epiomed Therapeutics, Inc. 17
InnoPharma, Inc. 18
Emesis (Vomiting) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Molecule Type 24
Drug Profiles 26
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DWJ-1308 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ETI-0001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ETI-385 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FK-886 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IP-117 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IP-123 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Emesis (Vomiting) - Recent Pipeline Updates 34
Emesis (Vomiting) - Dormant Projects 35
Emesis (Vomiting) - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Emesis (Vomiting), H2 2014 7
Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Emesis (Vomiting) - Pipeline by Astellas Pharma Inc., H2 2014 15
Emesis (Vomiting) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 16
Emesis (Vomiting) - Pipeline by Epiomed Therapeutics, Inc., H2 2014 17
Emesis (Vomiting) - Pipeline by InnoPharma, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Emesis (Vomiting) Therapeutics - Recent Pipeline Updates, H2 2014 34
Emesis (Vomiting) - Dormant Projects, H2 2014 35
Emesis (Vomiting) - Discontinued Products, H2 2014 36